Post by Future Biotech Expo

Johnson & Johnson has announced positive results from its Phase 3 MonumenTAL-3 clinical trial, highlighting the potential of a combination treatment featuring TALVEY (talquetamab-tgvs) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for patients with relapsed or refractory multiple myeloma. Read more: https://lnkd.in/gQYDaeiw #FBE26 #FutureBiotechExpo #Biotechnology #Pharma #LifeSciences #HealthcareInnovation #BiotechInnovation